The Somatic BRCA Test analyzes tumor tissue to detect acquired mutations in the BRCA1 and BRCA2 genes. Somatic mutations, acquired in cells during a person’s life rather than inherited, are a major driver of cancer development and progression. Detecting these alterations enables physicians to tailor treatment plans, including targeted therapies such as PARP inhibitors, which are particularly effective in patients with BRCA mutations.
Genes Covered: BRCA1, BRCA2
Who Is This Test For?
Patients diagnosed with cancers commonly associated with BRCA mutations, such as breast, ovarian, prostate, and pancreatic cancer.
Key Features
Targets somatic (tumor-acquired) mutations in BRCA1 and BRCA2
Facilitates informed targeted therapy decisions
Applicable across multiple cancer types, including breast, ovarian, prostate, and pancreatic cancers
Clinical Applications
Guides the use of PARP inhibitors for eligible patients
